About the Conference
Molecular diagnostics along with healthcare in general are undergoing technology-driven revolution, and we are at the beginning of this exciting journey. Novel detection assays and sensors, digital biomarkers and machine learning approaches have
become key drivers for innovation in drug development and patient care. The channel will feature the latest technology breakthroughs as well as partnering, regulatory and reimbursement solutions for implementation into value-based patient-centered
care.
A PDX/Organoid Biobank of Advanced Prostate Cancer for Disease Modeling and Therapeutic Screening
Kathleen Kelly, PhD, Lab Chief, Laboratory of Genitourinary Cancer Pathogenesis, Center
for Cancer Research, National Cancer Institute
Advancing Cancer Diagnostics with Artificial Intelligence
Martin Stumpe, PhD, Senior Vice President, Data Science, Tempus
QuPath: Digital Pathology for Everyone
Peter Bankhead, PhD, Senior Lecturer, Digital Pathology, University of Edinburgh
A Digital Platform Integrating Disease and Risk Factor Surveillance, Genomics and Continuous Glucose Monitoring (CGM) to Estimate Personalized 10-Year Mortality Risk
Bradley A. Perkins, MD, Co-Founder & CEO, Sapiens Data Science, Inc.
Harnessing Patient Biology and Artificial Intelligence to Enable a Biomarker-Driven Personalized Medicine Approach
Niven R. Narain, PhD, Co-Founder, President & CEO, BERG
KEYNOTE PRESENTATION: Digital Health and the Wired Person
Michael Snyder, PhD, Professor & Chair, Center for Genomics & Personalized Medicine, Stanford University
KEYNOTE PRESENTATION: Understanding Disease State through Sensors/Wearables
Anand Subramony, PhD, Vice President, Novel Product Technologies, MedImmune